In May 2025, the first head-to-head randomized trial between these four drugs finally landed. Tirzepatide produced 20.2% body weight loss at 72 weeks. Semaglutide produced 13.7%. One in three tirzepatide patients lost at least a quarter of their body weight. One in six semaglutide patients did. Ozempic vs Wegovy vs Mounjaro vs Zepbound is no longer a comparison between four products. It is a comparison between two molecules wearing four labels, and the molecule that wins on raw weight loss is clear.
The four-name confusion exists for a reason. Semaglutide is sold as Ozempic (T2D label) and Wegovy (weight-loss, cardiovascular, MASH, and pediatric labels). Tirzepatide is sold as Mounjaro (T2D label) and Zepbound (weight-loss and obstructive sleep apnea labels). Same drug inside each pen. Different label on the box. And the label, not the molecule, is what your insurance reads when it decides whether to pay. Roughly 14% of commercial plans offer unrestricted GLP-1 weight-loss coverage in 2026, so picking the wrong brand for your indication is often the difference between a $25 copay and a $1,000 cash bill.
In the next 3,200 words we walk through each brand with current 2026 pricing (NovoCare $349, LillyDirect $299 to $449, oral Wegovy $149 to $299), the label expansions that moved the answer in the last twelve months (Zepbound for OSA, Wegovy for MASH, oral Wegovy in December 2025, Wegovy HD 7.2 mg in March 2026), and a verdict that names which brand fits which situation. If you want the wider field that includes compounded tirzepatide and pipeline drugs, see our best GLP-1 medication breakdown.
The 2 Molecules, 4 Brands, and What the Label Actually Decides
Four brand names. Two drugs. One reason that decision matters more than anything else.
| Brand | Molecule | FDA Label | Dose Range |
|---|---|---|---|
| Ozempic | semaglutide | Type 2 diabetes (CV risk reduction in T2D + CVD) | 0.5 to 2 mg weekly |
| Wegovy | semaglutide | Weight management, CV risk reduction, MASH, pediatric 12+ | 0.25 to 2.4 mg (HD 7.2 mg as of March 2026) |
| Mounjaro | tirzepatide | Type 2 diabetes | 2.5 to 15 mg weekly |
| Zepbound | tirzepatide | Weight management, moderate-to-severe OSA | 2.5 to 15 mg weekly |
Your insurance plan does not look at the molecule. It looks at the FDA label. Consider what happened to a patient documented in GoodRx’s 2025 coverage analysis: Torres was prescribed Ozempic in January for type 2 diabetes, lost nearly 20% of her body weight, and then lost coverage because her T2D markers normalized and she no longer “qualified” for the diabetes diagnosis the prescription was tied to. The molecule had done exactly what it was supposed to do. The label was the trap.
The rule that follows from this: if you want insurance to cover weight loss, you need a weight-labeled product (Wegovy or Zepbound). If you have T2D, the T2D-labeled product (Ozempic or Mounjaro) is the cleanest insurance path. Off-label routes are legal, common, and almost never covered. Only about 14% of commercial plans offer unrestricted GLP-1 weight-loss coverage in 2026, and 2025 saw an additional 11% tightening of even on-label coverage.
Now the head-to-head data. SURMOUNT-5 (N=750, 72 weeks, NEJM May 2025) put tirzepatide and semaglutide against each other at maximum tolerated doses for the first time. Tirzepatide produced 20.2% mean body weight loss. Semaglutide produced 13.7%. Absolute kilograms lost: 22.8 vs 15.0. The proportion of patients hitting at least 25% weight loss: 32% on tirzepatide, 16% on semaglutide. For four years the comparison was indirect. Now it is on the record.
The wrinkle that arrived ten months later: Wegovy HD 7.2 mg, approved by the FDA on March 19, 2026, hit 20.7% mean weight loss in the STEP UP trial. About one in three patients on Wegovy HD achieved at least 25% loss. The efficacy gap with Zepbound is now within trial-design noise. Tirzepatide still wins for now. The gap is shrinking.
We will walk through the four brands in the order patients actually pick them for weight loss in 2026: Zepbound, Wegovy, Mounjaro, Ozempic.
1. Zepbound (Tirzepatide): The Weight-Loss Heavyweight With a Sleep Apnea Side Door
Zepbound produces the most weight loss of any branded GLP-1 in 2026, and 109 million commercially insured Americans have no coverage for it. Both of those things are true.
FDA label. Zepbound is approved for chronic weight management in adults with BMI of 30 or higher (or 27 with at least one comorbidity), and uniquely among the four, for moderate-to-severe obstructive sleep apnea in adults with obesity. The OSA approval landed in December 2024 based on SURMOUNT-OSA. Zepbound reduced apnea-hypopnea index by 25 to 29 events per hour vs 5 to 6 with placebo. Between 42% and 50% of patients achieved OSA remission or mild classification at one year, depending on whether they were also using PAP therapy.
Real-world efficacy. At maximum tolerated dose in SURMOUNT-5, Zepbound delivered 20.2% mean weight loss over 72 weeks vs Wegovy’s 13.7%. Where the gap really shows: 64.6% of Zepbound patients hit at least 15% weight loss vs 40.1% of Wegovy patients, and 32% lost at least 25% of starting body weight vs 16% on Wegovy. Terra Field, 43, captured the switching narrative in a widely reported case: she lost more than 100 pounds in two and a half years on Wegovy, plateaued in early 2025, switched to Zepbound, and immediately watched the scale move again. Her experience tracks what the trial data predicts.
Side-effect profile. Nausea on Zepbound (44%) is identical to Wegovy. The differences show up downstream. Vomiting is 15% vs 21% on Wegovy. GERD is 6% vs 11%. Injection-site irritation is higher on Zepbound (9% vs under 1%), a real annoyance that doesn’t show up in efficacy data. The most consequential number: GI-related discontinuation is 2.7% on Zepbound vs 5.6% on Wegovy. Patients are about half as likely to quit Zepbound for digestive reasons. Drugs.com aggregates 655 patient reviews at 8.7/10, with 80% reporting a positive experience.
2026 pricing. LillyDirect cash pay: 2.5 mg vials at $299/month, 5 mg at $399, 7.5 to 15 mg at $449 (refill within 45 days to keep pricing). TrumpRx, the government platform launched February 2026, lists Zepbound starting at $299 and averaging $346. Both programs ship single-dose vials, not pens. Neither counts toward your insurance deductible or out-of-pocket maximum. And here is the gotcha that surprises every Medicare patient: NovoCare, LillyDirect, and TrumpRx savings are unavailable to Medicare, Medicaid, Tricare, and VA beneficiaries. Full list price applies. The one exception worth knowing: if you have an OSA diagnosis, Medicare Part D may cover Zepbound for sleep apnea even when weight-loss coverage is excluded, and UnitedHealthcare runs a 6-month prior authorization for OSA separately from any weight-loss request.
Best for: adults with BMI of 30 or higher who want maximum weight loss, anyone with obesity plus moderate-to-severe OSA, and patients who plateaued on Wegovy and are ready to switch molecules.
Skip if: you are needle-averse (no oral form exists), under 18 (not approved), or on Medicare for weight loss alone (the savings card cannot help you).
2. Wegovy (Semaglutide): The Brand That Keeps Expanding Its Label
Wegovy lost the head-to-head to Zepbound in May 2025. By March 2026, it had four label expansions, a new oral pill, and a $349 cash price. No other brand in this comparison moved as much in twelve months.
FDA labels (plural). Wegovy is approved for adults with BMI 30 or higher (or 27 with comorbidity), adolescents 12 and up with obesity (2022), cardiovascular risk reduction in adults with overweight or obesity and established CVD (2024, SELECT), and noncirrhotic MASH with moderate-to-advanced liver fibrosis (2025, ESSENCE). That is more label coverage than the other three branded products combined. Each label is a separate prescriber lane. The ESSENCE data on its own: 63% of Wegovy patients achieved steatohepatitis resolution at 72 weeks vs 34% on placebo, with 37% achieving fibrosis improvement vs 22%.
Real-world efficacy and Wegovy HD. Standard Wegovy at 2.4 mg produces roughly 15% weight loss in pivotal trials and 13.7% vs Zepbound’s 20.2% in SURMOUNT-5. Then March 2026 changed the math. Wegovy HD (7.2 mg) hit 20.7% mean weight loss in STEP UP, with about one in three patients losing at least 25%. The efficacy gap with Zepbound is now within trial-design margin. On the cardiovascular side, SELECT remains the strongest dedicated evidence in the weight-loss population: 17,604 non-diabetic adults with CVD, 39.8 months mean follow-up, 20% reduction in major adverse cardiovascular events.
Side effects and food noise. Nausea 44%, vomiting 21%, constipation 29%, GERD 11%, injection-site reactions under 1%. The GI burden runs higher than tirzepatide at maximum doses. The central-nervous-system effect is well documented. Novo Nordisk’s INFORM poll of 550 Wegovy patients (EASD 2025) found 62% reported constant food thoughts before treatment and only 16% during treatment. One patient quoted in the medino food-noise reporting put it directly: “I didn’t realize how loud the food noise was until it was gone. I kept waiting for the cravings to come back. They never did.”
Oral Wegovy. Approved December 22, 2025. A 25 mg tablet titrated from 1.5 mg to 4 mg to 9 mg to 25 mg over 90 days. The protocol is strict: fasting on waking, 4 oz of plain water or less, then 30 minutes before eating or other oral medications. OASIS 4 results: 13.6% weight loss intention-to-treat, 16.6% with full adherence at 64 weeks. Cash runs $149/month at starter and $299/month at maintenance, making it the cheapest branded GLP-1 in 2026.
2026 pricing. NovoCare self-pay dropped to $349/month for most Wegovy doses on November 17, 2025 (from $499). Through March 31, 2026, NovoCare ran a $199 introductory offer on 0.25 mg and 0.5 mg. Medicare, Medicaid, Tricare, and VA patients cannot use NovoCare. Oral Wegovy is expected on Medicare Part D from July 2026 at around $50/month under the GLP-1 Bridge program.
Direct recommendation: If you have obesity plus liver fibrosis, established cardiovascular disease, or you are a parent of a teenager 12 to 17 with obesity, or you would rather take a pill than an injection, Wegovy is your answer. If you are a non-diabetic adult focused purely on weight loss and your insurance covers both, Zepbound usually wins on efficacy. The gap is narrowing.
3. Mounjaro (Tirzepatide): The T2D Pathway to the Best Weight-Loss Molecule
If you do not have type 2 diabetes and your doctor wrote you a Mounjaro script for weight loss, your insurer is almost certainly going to deny it. The molecule is identical to Zepbound. The label is the difference.
FDA label. Mounjaro is approved for type 2 diabetes only, as an adjunct to diet and exercise to improve glycemic control in adults with T2D. Adults only (no pediatric approval). No OSA indication. No MASH indication. No obesity label. The label is narrow on purpose. Lilly built Zepbound to carry the obesity indication, and Mounjaro to carry the diabetes one, and the company structures pricing and patient-assistance programs accordingly.
Real-world use including off-label. For T2D patients who also want weight loss, Mounjaro is the cleanest insurance route to tirzepatide. At T2D doses of 5 to 15 mg, patients see the same weight loss as Zepbound users at the same dose, up to about 22.5% at 15 mg in SURMOUNT trials. Mounjaro is also prescribed off-label for non-diabetic patients, sometimes because samples are easier to access, but commercial coverage almost always denies non-T2D use.
Side-effect profile. Same molecule as Zepbound, same profile: nausea 44%, vomiting 15%, GERD 6%, injection-site irritation 9%, GI-related discontinuation 2.7%. Dr. Cecilia Low Wang at UCHealth frames tirzepatide as a “combination peptide” that activates both GLP-1 and GIP receptors. The GIP component has antiemetic properties via direct central action in the hindbrain, which helps explain why vomiting and GI discontinuation run lower on tirzepatide despite identical nausea rates. Mayo Clinic Connect forums regularly feature patients who describe tolerating tirzepatide better after struggling on semaglutide.
2026 pricing. Mounjaro cash list price runs $1,080 to $1,135/month. Lilly offers a savings card for commercially insured T2D patients that can drop copays to $25/month. LillyDirect does not currently sell Mounjaro at the discounted vial price Zepbound gets. T2D patients without coverage usually pay closer to list. Medicare Part D may cover Mounjaro for T2D depending on plan formulary.
Switching protocol. Moving from semaglutide (Ozempic or Wegovy) to tirzepatide (Mounjaro or Zepbound): take your last semaglutide dose on the normal schedule, wait one full week (roughly one semaglutide half-life), then start tirzepatide at 2.5 mg on the day your next semaglutide injection would have been due. Titrate by 2.5 mg every 4 weeks. Expect mild GI symptoms in weeks 1 and 2. There is no direct dose conversion.
Best for: adults with T2D who want one drug for both blood sugar and weight, patients who tolerated semaglutide poorly and want to try tirzepatide, and patients whose insurance formulary covers Mounjaro but not Zepbound (which happens often).
Skip if: you do not have T2D and you want insurance to cover weight loss (Zepbound is the right brand), you need a pediatric option, or your primary indication is OSA or MASH.
4. Ozempic (Semaglutide): The Diabetes Brand Everyone Asks for By Name
Ozempic is the most-searched GLP-1 brand in the world and the wrong choice for almost any non-diabetic person trying to lose weight. Only about 14% of commercial plans offer unrestricted GLP-1 weight-loss coverage in 2026, and Ozempic prescribed off-label is not in that 14%.
FDA label. Ozempic is approved for adults with type 2 diabetes as an adjunct to diet and exercise for glycemic control, and for reducing major adverse cardiovascular events in adults with T2D and established cardiovascular disease. Doses are 0.5 mg, 1 mg, and 2 mg weekly. Critically: Ozempic is not labeled for weight loss, and the 2 mg max dose sits below Wegovy’s 2.4 mg maintenance dose and well below the 7.2 mg of Wegovy HD. Even when the molecule is the same, the dose ceiling caps the result.
Real-world use including off-label. Doctors prescribe Ozempic off-label for weight loss for predictable reasons: physician familiarity is high, samples are easier to get, smaller pens feel less intimidating, and T2D cardiovascular outcomes data sometimes gets misread as applying to non-diabetics. The clinical reality at 2 mg is modest. In T2D trials, semaglutide at 2 mg produces roughly 6% to 7% body weight loss, well below Wegovy’s 15% at 2.4 mg or Zepbound’s 22.5% at 15 mg. The Torres case applies here: off-label Ozempic almost always means cash, and even for T2D patients, coverage can disappear once weight loss normalizes markers.
Side-effect profile. Same molecule as Wegovy at lower doses, so generally better tolerated than max-dose Wegovy. Nausea dominates the complaint list, but at 0.5 to 1 mg many patients tolerate Ozempic well. A 2025 Healthline analysis of a Reddit study covering 410,198 GLP-1 posts found 43.5% of users mentioned at least one side effect, with hidden complaints clustering around menstrual irregularities and temperature regulation in addition to the standard GI list.
2026 pricing. Ozempic list runs $968 to $1,029/month. NovoCare self-pay at $349/month applies to Ozempic 0.5 mg and 1 mg for commercially insured patients without coverage. Ozempic 2 mg stays at $499. The $199 introductory NovoCare offer through March 31, 2026 is Wegovy-only. For T2D patients with commercial insurance, a savings card can drop the copay to $25. For non-T2D off-label use, manufacturer assistance is functionally absent.
Quick comparison vs alternative. If your goal is weight loss and you are choosing between Ozempic off-label and Wegovy on-label, Wegovy wins on three counts: a higher max dose (2.4 mg standard or 7.2 mg HD vs Ozempic’s 2 mg), a label that insurers recognize for weight loss, and NovoCare $349 cash pricing if coverage is denied. The only time Ozempic is the right pick over Wegovy is when you have T2D. Then it becomes the cleaner insurance path.
The Bottom Line: How to Pick the Right Brand for Your Situation
Forget the matrix. Here is the decision in seven situations. Find yours and you have your brand.
-
You have T2D and want both glycemic control and weight loss. Mounjaro is the better choice for weight loss at T2D doses. Ozempic is the cheaper option if cost is a barrier and you need only modest weight reduction alongside glucose control.
-
Non-diabetic adult, maximum weight loss is the goal, insurance covers it. Zepbound. Highest efficacy in head-to-head (20.2% vs 13.7%), and 64.6% of patients hit at least 15% loss.
-
Non-diabetic adult, insurance denied Zepbound, you are paying cash. Wegovy via NovoCare at $349/month for most doses, or oral Wegovy at $149 to $299/month if needles are a barrier. Both beat list-price Zepbound on cost.
-
You have obesity plus moderate-to-severe obstructive sleep apnea. Zepbound. Only one of the four with an OSA approval, and Medicare Part D may cover for OSA even when weight loss is excluded.
-
You have obesity plus MASH with moderate-to-advanced liver fibrosis. Wegovy. Only one of the four approved for MASH. Your hepatologist can prescribe.
-
You are a parent of a teenager 12 to 17 with obesity. Wegovy. Only one approved for adolescents. The pivotal trial showed 73% of patients losing at least 5% body weight at 68 weeks.
-
You have plateaued on semaglutide (Wegovy or Ozempic). Switch to tirzepatide. Zepbound if you are non-diabetic, Mounjaro if you have T2D. One-week washout, restart at 2.5 mg, titrate every 4 weeks.
Before your appointment, confirm your plan’s formulary, get your BMI and any comorbidities documented in your chart, and ask your prescriber for the specific brand by name rather than letting the office default to whatever is on the sample shelf. For options beyond these four brands (compounded tirzepatide, oral semaglutide alternatives, and the next wave of GLP-1 drugs in the pipeline), see our full GLP-1 medication guide.
Frequently Asked Questions
My doctor prescribed Ozempic for weight loss but I don’t have diabetes. Will insurance cover it?
Almost certainly not. Most commercial plans explicitly exclude off-label weight-loss Ozempic, and only about 14% of plans offer unrestricted GLP-1 weight-loss coverage in 2026. Ask your doctor to switch the script to Wegovy (same molecule, on-label) before prior authorization.
Does Zepbound really have less nausea than Wegovy?
The nausea rate is identical in the head-to-head trial: 44% on both. Zepbound wins on the complications downstream. Vomiting 15% vs 21%, GERD 6% vs 11%, and GI-related discontinuation 2.7% vs 5.6%. Patients are about half as likely to quit Zepbound for digestive reasons.
Can I use the NovoCare $349 or LillyDirect savings if I’m on Medicare?
No. NovoCare, LillyDirect, and TrumpRx are all unavailable to Medicare, Medicaid, Tricare, and VA beneficiaries. Medicare Part D may cover Zepbound for OSA and oral Wegovy from July 2026 under the GLP-1 Bridge program. For weight loss alone on Medicare, options remain limited.
Is there an option for someone who hates needles?
Yes. Oral Wegovy, a 25 mg semaglutide tablet, launched January 2026. Cash pricing is $149 to $299/month, and weight loss in OASIS 4 ran 13.6% to 16.6% at 64 weeks. The protocol catch: take fasting with 4 oz of plain water, then wait 30 minutes before eating.
Can my teenager take any of these?
Only Wegovy is FDA-approved for ages 12 to 17 with obesity. In the pivotal trial, BMI dropped 16.1% at 68 weeks and 73% of patients lost at least 5% of body weight. Mounjaro, Zepbound, and Ozempic are adults-only.
What happens if I stop taking the medication?
Most patients regain 70% to 80% of lost weight within one year of stopping without medical supervision. Real-world data shows fewer than 1 in 4 patients remain on any GLP-1 after a year. Plan for these as long-term tools, not short-term interventions.